subscribeSubscribe
Enforcement Report - Week of April 24, 2024

Enforcement Report - Week of April 24, 2024
FDA
24 Apr 2024
Share Share
AvKARE, LLC. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension

AvKARE, LLC. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension
FDA
02 Apr 2024
Share Share
Enforcement Report - Week of May 17, 2023

Enforcement Report - Week of May 17, 2023
FDA
17 May 2023
Share Share
Camber recalls pneumonia drug, citing possible contamination

Camber recalls pneumonia drug, citing possible contamination
Joseph Keenan FIERCE PHARMA
04 Apr 2023
Share Share
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product
FDA
31 Mar 2023
Share Share
USFDA gives exception to Glenmark to supply pneumonia drug from Baddi facility

USFDA gives exception to Glenmark to supply pneumonia drug from Baddi facility
ECONOMIC TIMES
27 Jan 2023
Share Share
Abon Pharma’s Generics Atovaquone Receives Approvals In US

Abon Pharma’s Generics Atovaquone Receives Approvals In US
FDA
27 Oct 2021
Share Share
Enforcement Report - Week of September 1, 2021

Enforcement Report - Week of September 1, 2021
FDA
01 Sep 2021
Share Share
KVK Tech Inc., Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension

KVK Tech Inc., Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension
FDA
07 Aug 2021
Share Share
TGen and HonorHealth trial atovaquone plus azithromycin for Covid-19

TGen and HonorHealth trial atovaquone plus azithromycin for Covid-19
CLINICALTRIALSARENA
06 May 2020
Share Share